The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents

American Heart Journal

Volumn 157, Issue 5, 2009, Pages 899-907

  Butler, Michelle J ^a   Eccleston, David ^b   Clark, David J ^c   Ajani, Andrew E ^b,d   Andrianopoulos, Nick ^d   Brennan, Angela ^d   New, Gishel ^e   Black, Alexander ^f   Szto, Gregory ^g   Reid, Chris M ^d   Yan, Bryan P ^b   Shaw, James A ^a   Dart, Anthony M ^a   Duffy, Stephen J ^a,d  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d Centre of Cardiovascular Research   (Australia)

^e BOX HILL HOSPITAL   (Australia)

^f GEELONG HOSPITAL   (Australia)

^g FRANKSTON HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BARE METAL STENT; CONFIDENCE INTERVAL; DATA ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; STATISTICAL ANALYSIS; STENT THROMBOSIS; SURVIVAL; TREATMENT DURATION; TREATMENT PLANNING;

AGED; CORONARY STENOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; VICTORIA;

EID: 64349108126     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.02.018     Document Type: Article

References (31)

1. Hall P., Nakamura S., Maiello L., et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93 (1996) 215-222
2. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
3. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
4. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
5. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
6. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
7. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
8. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
9. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
10. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
11. Farb A., and Boam A.B. Stent thrombosis redux-the FDA perspective. N Engl J Med 356 (2007) 984-987
12. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
13. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
14. Ong A.T., McFadden E.P., Regar E., et al. Late Angiographic Stent Thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
15. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
16. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
17. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
18. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
19. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
20. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
21. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
22. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
23. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 115 (2007) 813-818
24. Yan B.P., Ajani A.E., Duffy S.J., et al. Use of drug-eluting stents in Victorian public hospitals. Med J Aust 185 (2006) 363-367
25. Ajani A.E., Szto G., Duffy S.J., et al. The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project. Heart Lung Circ 15 (2006) 44-47
26. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
27. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
28. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
29. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
30. Meier P., Zbinden R., Togni M., et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 49 (2007) 15-20
31. Chen M.S., John J.M., Chew D.P., et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 (2006) 1260-1264